Discover open access scientific publications

Search, annotate, share and cite publications

Publications by T Alnadaf

Combination of Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Required for Resistance to the Carbocyclic Nucleoside 1592U89.

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

1997

English

Related publications

Frequency of Mutations Conferring Resistance to Nucleoside Reverse Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1-Infected Patients in Korea

Journal of Clinical Microbiology

Microbiology

2002

English

Modulation of Human Immunodeficiency Virus Type 1 Synergistic Inhibition by Reverse Transcriptase Mutations

English

Nonpolymorphic Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Treatment-Selected Mutations

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

2009

English

Antiviral Drug Resistance Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Occur in Specific RNA Structural Regions.

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

1994

English

Substrate Inhibition of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase.

Proceedings of the National Academy of Sciences of the United States of America

Multidisciplinary

1991

English

Mechanistic Insights Into the Suppression of Drug Resistance by Human Immunodeficiency Virus Type 1 Reverse Transcriptase Using Α-Boranophosphate Nucleoside Analogs

Journal of Biological Chemistry

English

RNA Pseudoknots That Inhibit Human Immunodeficiency Virus Type 1 Reverse Transcriptase.

Proceedings of the National Academy of Sciences of the United States of America

Multidisciplinary

1992

English

Coresistance to Zidovudine and Foscarnet Is Associated With Multiple Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

1998

English

Increased Polymerase Fidelity of E89G, a Nucleoside Analog-Resistant Variant of Human Immunodeficiency Virus Type 1 Reverse Transcriptase.

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by T Alnadaf

Combination of Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Required for Resistance to the Carbocyclic Nucleoside 1592U89.

Related publications

Frequency of Mutations Conferring Resistance to Nucleoside Reverse Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1-Infected Patients in Korea

Modulation of Human Immunodeficiency Virus Type 1 Synergistic Inhibition by Reverse Transcriptase Mutations

Nonpolymorphic Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Treatment-Selected Mutations

Antiviral Drug Resistance Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Occur in Specific RNA Structural Regions.

Substrate Inhibition of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase.

Mechanistic Insights Into the Suppression of Drug Resistance by Human Immunodeficiency Virus Type 1 Reverse Transcriptase Using Α-Boranophosphate Nucleoside Analogs

RNA Pseudoknots That Inhibit Human Immunodeficiency Virus Type 1 Reverse Transcriptase.

Coresistance to Zidovudine and Foscarnet Is Associated With Multiple Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase

Increased Polymerase Fidelity of E89G, a Nucleoside Analog-Resistant Variant of Human Immunodeficiency Virus Type 1 Reverse Transcriptase.